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1046 ABDEL-AZIZ ET ALBackground: Electronic noses (eNoses) are emerging point-of-
care tools that may help in the subphenotyping of chronic
respiratory diseases such as asthma.
Objective: We aimed to investigate whether eNoses can classify
atopy in pediatric and adult patients with asthma.
Methods: Participants with asthma and/or wheezing from 4
independent cohorts were included; BreathCloud participants
(n 5 429), Unbiased Biomarkers in Prediction of Respiratory
Disease Outcomes adults (n 5 96), Unbiased Biomarkers in
Prediction of Respiratory Disease Outcomes pediatric
participants (n 5 100), and Pharmacogenetics of Asthma
Medication in Children: Medication with Anti-Inflammatory
Effects 2 participants (n 5 30). Atopy was defined as a positive
skin prick test result (>_3 mm) and/or a positive specific IgE level
(>_0.35 kU/L) for common allergens. Exhaled breath profiles were
measured by using either an integrated eNose platform or the
SpiroNose. Data were divided into 2 training and 2 validation sets
according to the technology used. Supervised data analysis
involved the use of 3 different machine learning algorithms to
classify patients with atopic versus nonatopic asthma with
reporting of areas under the receiver operating characteristic
curves as a measure of model performance. In addition, an
unsupervised approach was performed by using a bayesian
network to reveal data-driven relationships between eNose
volatile organic compound profiles and asthma characteristics.
Results: Breath profiles of 655 participants (n 5 601 adults and
school-aged children with asthma and 54 preschool children
with wheezing [68.2% of whom were atopic]) were included in
this study. Machine learning models utilizing volatile organic
compound profiles discriminated between atopic and nonatopic
participants with areas under the receiver operating
characteristic curves of at least 0.84 and 0.72 in the training and
validation sets, respectively. The unsupervised approach
revealed that breath profiles classifying atopy are not
confounded by other patient characteristics.
Conclusion: eNoses accurately detect atopy in individuals with
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Describing asthma as extrinsic (atopic) and intrinsic (non-
atopic) was an early attempt to classify the disease into subgroups
based on sensitization to common aeroallergens.1 However,
asthma is now recognized as a complex, heterogeneous, chronic
inflammatory disease comprising different clinical and biologic
mechanisms other than allergic sensitization (atopy). Nonethe-
less, atopy is among the most consistent characteristics associated
with certain asthma phenotypes when data-driven methods are
used.2-6 This suggests that atopy and its underlying biologic
pathway may be a driving factor of certain asthma-associated
phenotypes andmay thus play an important role in the pathophys-
iology of the disease process. Therefore, atopy (or its associated
phenotypes) must be characterized as a marker of disease severity
and/or a treatable trait in asthma precision medicine.
The diagnosis of atopy is based on allergen-specific IgE
measurement and/or skin prick test (SPT) results with predefined
allergens.7 Although an SPT is faster to perform (usually within
15-20 minutes) than in vitro measurement of allergen-specific
IgEs,8 it is relatively invasive and may lead to redness, swelling,
itching, and bleeding, as well as to delayed allergic skin reaction
and, in some rare circumstances, anaphylactic reactions.8-10 Also,
it is of limited use in patients with severe dermatologic conditions
or those taking antihistamine (and several other) medications8
which is common in patients with asthma.11 Conversely,
allergen-specific IgE measurements are more costly, they require
venepuncture, and their results are usually not immediately
available.8
Electronic noses (eNoses) are emerging point-of-care tools for
diagnosing and phenotyping different respiratory diseases,
including asthma.12-14 They are cheap and easy to use, and the
samples can be collected quickly. They can be used during a doc-
tor’s visit with immediate results, which could be beneficial in theemployee of Danone Nutricia Research. P. J. Sterk reports grants from the Public-
Private Innovative Medicines Initiative covered by the European Union and the
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Medication with Anti-Inflammatory Effects 2ppb: Parts per billionsPLS-DA: Sparse partial least squares discriminant analysisSPT: Skin prick testU-BIOPRED: Unbiased Biomarkers in Prediction of Respiratory
Disease OutcomesVOC: Volatile organic compoundclinical decision-making process. eNoses consist of multiple
cross-reactive sensors that enable pattern recognition of the
complete mixture of volatile organic compounds (VOCs) without
identifying their molecular entities,15,16 creating unique breath
profiles for individual subjects. Clustering techniques on eNose
breath profiles of both adult and pediatric patients with asthma
have identified asthma phenotypes with differences in atopy, in-
flammatory biomarkers, and other characteristics.12,13,17
In this study, we aimed to investigate whether exhaled breath
profiles generated by eNose platforms can discriminate between
patients with atopic asthma and patients with nonatopic asthma,
following the Standards for Reporting Diagnostic Accuracy
guidelines.18 We hypothesized that assessment of VOCs in
exhaled breath offers a fast and noninvasive diagnostic
biomarker for atopic asthma, offering a precision medicine
tool by characterizing atopy-associated treatable traits in
asthma, and hence, directing treatment decisions to the needs
of individual patients.METHODS
Subjects
Adult and pediatric participants from 4 independent asthma cohorts were
included in this analysis: the Unbiased BIOmarkers in PREDiction of
respiratory disease outcomes (U-BIOPRED) adult and pediatric cohorts,19,20
the BreathCloud asthma cohort,12 and the Pharmacogenetics of AsthmaMedi-
cation in Children: Medication with Anti-inflammatory Effects 2 (PAC-
MAN2) cohort.21 Most participants had mild-to-moderate or severe asthma;
the only exception was a subset of preschoolers within the U-BIOPRED pedi-
atric cohort with wheezing (n5 54). For a brief summary of the included co-
horts, see Table E1 (in this article’s Online Repository at www.jacionline.org).
The flow diagram for patient inclusion is shown in Fig 1.Outcome definition
Atopywas defined as a positive SPT result, defined by awheal diameter of 3
mm or more and/or a positive allergen-specific IgE level of at least 0.35 kU/L
to a prespecified allergen listed in Table E2 (in this article’s Online Repository
at www.jacionline.org). This list represents the most common allergens
encountered at the study recruiting centers. Table E3 (in this article’s Online
Repository at www.jacionline.org) shows the main allergen category and the
type of the test used to diagnose atopy in each included cohort.Noninvasive exhaled breath measurements
Exhaled VOCs. Offline eNose technology was used to measure
exhaled breath VOCs in U-BIOPRED and PACMAN2 cohorts, whereas real-
time eNose technology (SpiroNose, Amsterdam UMC, University of Am-
sterdam, Amsterdam, The Netherlands) was used to measure exhaled
VOCs in BreathCloud, as described previously in detail.12-14 We followed
standard operating procedures for breath collection by using validated instru-
ments.12-14,22,23 The exhaled breath measurement is depicted schematically in
Fig 2 and described in more detail in this article’s Online Repository at www.
jacionline.org. The highest sensitivities of the SpiroNose sensors to different
mixtures of volatile organic compounds (VOCs)/gases are shown in Table E4.
FENO value. Fractional exhaled nitric oxide (FENO) values in parts per
billion (ppb) were measured at a constant flow rate of 50 mL/s by using a
portable analyzer (NIOXMino System, Aerocrine, Solna, Sweden) according
to the American Thoracic Society/European Respiratory Society recommen-
dations.24 FENO measurements were available for a subset of patients in
each cohort.Data analysis
Ageneral overview of the data analysis approach used is provided in Fig E1
(in this article’s Online Repository at www.jacionline.org).
Supervised analysis with machine learning models.
To investigate the discriminative potential of the eNose sensors to classify
atopic versus nonatopic subjects, we applied a supervised machine learning
approach using differentmachine learningmodels.25 The classification perfor-
mance (high vs low) of the same machine learning model has been reported to
vary by data set and/or cohort.26,27 Building conclusions on a single classifi-
cation model may be biased and reduce potential validation, hence hindering
biomarker discovery. As proof of concept, we used the following 3 different
and powerful machine learning techniques modeled on eNose signals that
were previously used in metabolomics research25-27: sparse partial least
squares discriminant analysis (sPLS-DA),28 adaptive least absolute shrinkage
and selection operator (LASSO),29 and gradient boosting machine (GBM).30
This was to provide an estimate of the robustness of statistical performance
across different models and to evaluate eNose accuracy in classifying patients
with atopic asthma without bias from ‘‘single-model selection.’’ The 3
methods were selected on the basis of merit of feature reduction (selection),
which avoids the risk of model overfitting. For more details, see the Online
Repository.
Individual cohort classification with internal cross-
validation. For each cohort, atopic and nonatopic participants were
classified by using the eNose-drivenmodels (sPLS-DA,Adaptive LASSO, and
GBM). For internal validation, 10-fold cross-validation (50 repeats for model
tuning and prediction estimation, see details in Table E5 in this article’s Online
Repository at www.jacionline.org) was implemented in each model as
recommended.31Classification using training and validation sets in
the pooled cohorts and the BreathCloud cohort
Data sets from the 3 independent cohorts (U-BIOPRED adults,
U-BIOPRED pediatric patients, and PACMAN2) that used the same eNose
platform for offline breath analysis were combined (pooled cohorts)
because internal validation alone cannot assess the robustness of the eNose
sensors to detect atopy in independent validation sets. ComBat batch
correction32 was applied to the combined sensor data, and normal distribu-
tions were assessed by using histograms. The pooled data set was then
randomly divided into a training set and a validation set by using an approx-
imate ratio of 0.75:0.25 as recommended.12,31 The latter step was also
applied to the BreathCloud cohort by using the SpiroNose for real-time
breath analysis, resulting in 2 training sets and 2 validation sets (Fig 1).
The calculation of sample size of the training and validation sets on the basis
of the measure of area under the receiver operating characteristic curve
(AUROCC) is explained in the Online Repository. The training data sets
FIG 1. Flowchart for the included participants from 4 independent asthma cohorts. *The eNose platform is a
composite of 4 differently developed eNoses (Cyranose C320, Tor Vergata, Comon Invent, and Owlstone
Lonestar). {The term inclusion criteria violator refers to participants excluded from the analysis because of
violation of the inclusion criteria defined by the U-BIOPRED. # The term uncertain atopy diagnosis refers to
patients who do not have confirmed diagnoses for atopy by either SPT result or allergen-specific IgE level.
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procedure (50 repeats for model tuning and prediction estimation, see de-
tails in Table E5). The predictive potential of the fitted models was assessed
in the validation sets.
The performance of the obtained classification/predictive model was
evaluated by computing the AUROCCs and associated model accuracies,
specificities, and sensitivities. To calculate 95% CIs, error estimates were
obtained by performing 2000 nonparametric stratified bootstrapped replicates
using random sampling with replacement and with the percentile method.33,34
Differences in performance between the applied machine learning models
were estimated by performing pairwise comparison of the obtained
AUROCCs using the Venkatraman method35 (1000 permutations).
Sensitivity analysis after exclusion of nonaeroaller-
gens. A sensitivity analysis was performed to check whether the
discrimination using eNoses would change if patients sensitized with
nonaeroallergens (eg, food, latex) were excluded. Pairwise comparisons of
the AUROCCs obtained before and after exclusion of patients with non-
aeroallergen sensitization were estimated by using the Venkatramanmethod35
(1000 permutations).
Unsupervised investigation of atopy and data-driven
potential confounders. As exhaled breath is an emerging research
field, there is no adequate information in the literature on the possible
confounding factors that should be considered or adjusted for. Unsupervised
data-driven approaches such as bayesian networks (BNs) may provide an
opportunity to reveal or select hidden confounders36 in metabolomics breath
research. The BreathCloud data set was used in this analysis as it was the
largest breath cohort with available information on smoking, dietary intake
and time of food/drink consumption, and environmental factors (related to
ambient conditions), as well as information on demographics, spirometry re-
sults, inflammatory parameters, and asthma medications.
BNs. Unsupervised learning of the BN was performed on the complete
BreathCloud data set (Table E6). More details are provided in the Online
Repository. The final network was depicted by using Cytoscape,37 version3.7.1, showing the probabilistic relationship between different variables in
the form of a directed acyclic graph (DAG).
Discriminative ability of FENO value to classify atopic
versus nonatopic asthma. A receiver operating characteristic curve
was generated to assess the accuracy of FENO value in discrimination of pa-
tients with atopic asthma from those with nonatopic asthma. Continuous
FENO values (in ppb) pooled from all cohorts (the BreathCloud, PACMAN2,
and U-BIOPRED cohorts) were used in this analysis. Subsequently, different
clinically utilized cutoff values (>20, >35, and >50 ppb) were used to catego-
rize high and low FENO values to investigate whether these cutoffs would pro-
vide better insight than the uncategorized continuous values. These cutoffs
were chosen on the basis of previous recommendations.38,39 AUROCCs
for classifying atopy with bootstrapped (2000 nonparametric stratified repli-
cates) CIs33,34 were constructed by using each measure (continuous and
categorized).
All analyses were performed by using R studio (version 1.2.1335) with R
software (version 3.6.1) supported with the following packages: mixOmics,
glmnet, gbm, caret, pROC, boot, wiseR, and bnlearn.RESULTS
eNose data from a total of 655 participants (98 school-aged
children with asthma, 54 preschool children with wheezing, and
503 adults with asthma) were included in this study (Table I). The
prevalence of atopy within the different cohorts ranged from 63%
to 83%. Most atopic patients (412 of 447 [92.2%]) had sensitiza-
tion to at least 1 aeroallergen.
FIG 2. Exhaled breath measurement using the eNose platform (U-BIOPRED adults, U-BIOPRED pediatric,
and PACMAN2 cohorts) and the SpiroNose (BreathCloud). (Upper panel) Breath collection and measure-
ment using the eNoses platform in U-BIOPRED adult, U-BIOPRED pediatric, and PACMAN2 cohorts. Sub-
jects exhaled a single vital capacity volume into a 10-L Tedlar bag (SKC, Eighty Four, Pa), followed by
sampling of air on a Tenax thermal desorption tube (Tenax GR SS 6 mm 3 7 in; Gerstel, M€ulheim an der
Ruhr, Germany) to capture VOCs. A thermal desorption oven was used for desorption of the VOCs from
the tubes, which were then transferred to a Tedlar bag by using a carrier nitrogen gas. Subsequent detection
of the signal pattern of the VOC mixture was performed via multiple cross-reactive sensors in a composite
eNoses platform. (Lower panel) Real-time collection of the exhaled breath using the SpiroNose in the
BreathCloud cohort. Patients were instructed to perform 5 tidal breaths, followed by inspiration of a single
vital capacity volume, a breath hold for 5 seconds, and then expiration toward residual volume. The sen-
sors’ signals are recorded in real-time by the SpiroNose and transferred to a cloud environment for further
automated analysis. IMS, Ion mobility spectrometry;MOS, metal oxide semiconductor;QMB, quartz crystal
microbalance.
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breath profiles with internal cross-validation
Patients with atopic versus nonatopic asthma were classified
into the 4 independent cohorts by using 3 different machine
learning models (sPLS-DA, adaptive LASSO, and GBM), with
the representative AUROCCs shown in Fig 3. For each individual
cohort, the obtained AUROCCs were at least 0.85.Classification using exhaled breath profiles with
training and validation sets in the pooled cohorts
and the BreathCloud cohort
The predictive performance of the trained machine learning
models was evaluated in 2 validation sets showing relatively high
AUROCCs of at least 0.72 and 0.91 in the pooled cohorts and
BreathCloud, respectively, as shown in Fig 4 (pooled cohorts) and
Fig 5 (BreathCloud). The associated accuracies, specificities, and
sensitivities and their 95% CIs are also shown (Figs 4 and 5 and
see Table E7 in this article’s Online Repository at www.
jacionline.org). In the pooled cohorts, most discriminative signalswere derived from the Owlstone Lonestar system (Owlstone
Medical, Cambridge, UK), whereas in the BreathCloud cohort,
the sensor peak–to–breath hold ratios (see Fig E2 in this article’s
Online Repository at www.jacionline.org) contributed most to the
discriminative signal (data not shown). The GBM model perfor-
mance in the training sets (pooled cohorts and BreathCloud)
was better than either the sPLS-DA or adaptive LASSO models,
as estimated by higher AUROCCs with use of the Venkatraman’s
test (see Table E8 in this article’s Online Repository at
www.jacionline.org). However, this outperformance was elimi-
nated when model predictions were applied to the validation sets.Sensitivity analysis after exclusion of
nonaeroallergens
The AUROCCs obtained after exclusion of patients sensitized
with nonaeroallergens were relatively similar to the previous
findings in both the training and validation sets (see Table E9 in
this article’s Online Repository at www.jacionline.org). The
TABLE I. Participant baseline characteristics
Characteristic
U-BIOPRED
adults (n 5 96)
BreathCloud
(n 5 429)
U-BIOPRED pediatric
patients (n 5 100)
PACMAN2
(n 5 30)
Age (y), median (IQR) 55.0 (43.0-62.0) 50.0 (34.0-62.0) 5.0 (4.0-12.8) 11.5 (9.8-13.6)
Age group, no. (%)
Adults (>_18 y) 96 (100%) 407 (94.9%) NA NA
Children (<18 y) NA 22 (5.1%) 100 (100%) 30 (100%)
Females, no. (%) 54 (56.3%) 252 (58.7%) 36 (35%) 16 (53.3%)
BMI (kg/m2), median (IQR) 26.9 (23.9-32.5) 26.9 (23.5-30.6) 16.6 (15.4-19.7) 18.3 (17.3-19.7)
BMI (kg/m2) z score, median (IQR) 1.3 (0.4-2.5) 1.3 (0.4-2.1) 0.3 (-0.4-1.1) 0.1 (-0.6-1.1)
White race, no. (%) 90 (93.8%) 366 (85.3%) 75 (75%) 30 (100%)
Atopy, no. (%) 70 (72.9%) 289 (67.4%) 63 (63%) 25 (83.3%)
Aeroallergen 63 (65.6%) 266 (62%) 59 (59%) 24 (80%)
Nonaeroallergen 7 (7.3%) 23 (5.4%) 4 (4%) 1 (3.3%)
Current smokers, no. (%) 26 (27.1%) 45 (10.5%) NA NA
Patient class
With asthma, no. (%) 96 (100%) 429 (100%) 46 (46%) 30 (100%)
With preschool wheezing NA NA 54 (54%) NA
FEV1 % predicted before salbutamol, median (IQR) 67.8 (54.8-87.6) 86.0 (74.0-100.5) 93.9 (82.5-106.3) 86.5 (78.0-96.5)
FEV1 % predicted after salbutamol, median (IQR)* 81.3 (64.1-100.0) 92.0 (80.0-101.8) 101.5 (91.8-112.1) 95.0 (83.0-101.0)
FEV1/FVC % predicted before salbutamol, median (IQR) 75.4 (76.1-88.2) 87.0 (75.0-97.0) 92.1 (82.6-100.9) 94.5 (88.5-100.3)
FEV1/FVC % predicted after salbutamol, median (IQR)* 80.6 (72.3-94.8) 89.0 (78.0-100.0) 97.9 (89.3-103.4) 98.0 (92.0-104.0)
FENO value in ppb, median (IQR) 28.0 (14.0-49.0)
(n 5 94)
21.0 (13.0-39.0)
(n 5 192)
30.0 (13.0-59.0)
(n 5 43)
28.0 (11.0-64.0)
(n 5 28)
FENO value in ppb, median (IQR)
Atopic subjects 25.0 (13.0-41.5)
(n 5 69)
22.0 (12.5-37.0)
(n 5 133)
35.5 (14.0-65.78)
(n 538)
35.0 (14.0-68.0)
(n 5 23)
Nonatopic subjects 34.0 (22.0-77.5)
(n 5 25)
20.0 (13.0-41.0)
(n 5 59)
12.00 (8.50-21.0)
(n 5 5)
11.0 (5.0-17.50)
(n 5 5)
ACQ5 score average, median (IQR) 1.8 (0.8-2.8) 1.4 (0.7-2.3) NA NA
ACT score average, median (IQR) NA NA 18.00 (13.8-21.0) 18 (9.8-21.3)
P(AQLQ) score average, median (IQR) 5.2 (3.8-5.9) NA 5.5 (4.0-6.8) 6.0 (5.1-6.5)
Current asthma medication used, no. (%)
ICS 96 (100%) 357 (83.2%) 86 (86%) 30 (100%)
SABA 61 (63.5%) 198 (46.2%) 92 (92%) 24 (80%)
LABA 78 (81.3%) 307 (71.6%) 52 (52%) 16 (53.3%)
OCS 38 (39.6%) 58 (13.5%) 6 (6%) 0 (0%)
Short-acting anticholinergic 2 (4.2%) 33 (7.7%) 1 (1%) 0 (0%)
Long-acting anticholinergic 24 (25%) 79 (18.4%) 0 (0%) 0 (0%)
Leukotriene antagonist 28 (29.2%) 78 (18.2%) 57 (57%) 2 (6.7%)
Theophylline 13 (13.5%) 2 (0.5%) 2 (2%) 0 (0%)
Antihistamine 9 (9.4%) 96 (22.4%) 9 (9%) NA
ACQ5, 5-Item Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; FVC, forced vital capacity; ICS, inhaled corticosteroid; IQR,
interquartile range; LABA, long-acting b-agonist; NA, not applicable (which corresponds to either data not measured in this cohort or not applicable regarding the cohort criteria);
P(AQLQ), Pediatric Asthma Quality of Life Questionnaire; SABA, short-acting b-agonist.
*In BreathCloud, the personal best measurements were reported for postbronchodilator FEV1 % predicted from data on routine clinical practice that were collected less than 12
months before the study visit.
In BreathCloud, FENO measurements were reported as corresponding to the latest recorded values in routine clinical practice.
Data were not available for the complete set of study participants.
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AUROCCs before and after exclusion of these patients.Data-driven BN
Fig E3 (in this article’s Online Repository at www.jacionline.
org) shows the DAG of a BN that reveals probabilistic associa-
tions between SpiroNose sensor signals against different patient
characteristics (including atopy) and other factors. The data-
driven BN shows no edges connecting the atopy-associated
VOC sensor signals and other measured characteristics. Other
VOC signals showed connection with eosinophils counts and
oral corticosteroid (OCS) use.FENO value in discriminating atopic and nonatopic
asthma
FENO values were available for a subset of patients within the
included cohorts (n5 357). Fig E4 (in this article’s Online Repos-
itory at www.jacionline.org) shows that FENO value did not accu-
rately discriminate between patients with atopic versus nonatopic
asthma when either the continuous values (AUROCC 5 0.51) or
the categorized estimates (AUROCC5 0.52 for FENO values >20
ppb, 0.49 for FENO values >35 ppb, and 0.50 for FENO values >50
ppb) were used.DISCUSSION
To our knowledge, this is the first study to investigate the ability
of eNose technology to detect atopy in patients with asthma
FIG 3. AUROCCs with bootstrapped 95% CIs for 3 different machine learning models classifying atopic
versus nonatopic asthma in the U-BIOPRED adult, BreathCloud, U-BIOPRED pediatric, and PACMAN2
cohorts. ALASSO, Adaptive LASSO; AUC, area under the curve.
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ABDEL-AZIZ ET AL 1051across different age groups. By using a composite of bench-
marking supervised and unsupervised analysis techniques to
analyze data on different eNose platforms used with 4 indepen-
dent cohorts, we have shown that different eNoses can appropri-
ately discriminate between individuals with atopic versus
nonatopic asthma. Importantly, we have shown that observations
made by using offline eNose technology are replicated with the
real-time SpiroNose technology where sensors are placed in line
with standard equipment for spirometry.
By testing the eNose technology separately in individual
cohorts, a highly discriminative signal between patients with
atopic versus nonatopic asthma was observed, as indicated by
the different cross-validated machine learning models showing
an AUROCC of at least 0.85. The eNose VOC profiles
distinguished both groups when the data on the 3 cohorts
obtained by using the same eNose platform for exhaled breath
analyses (U-BIOPRED adult, U-BIOPRED pediatric, and PAC-
MAN2 cohorts) were pooled, which suggests generalizability of
eNoses that probably capture certain distinct VOCs associated
with atopy. However, there was a slight decrease in performance
of the models in both the training and validation sets of the
pooled cohorts as compared with the performance in the
individual cohorts, with AUROCCs of at least 0.84 and 0.72,respectively. This decrease may be related to differences in
study populations with respect to age and asthma-associated
characteristics and, possibly, to different eNose batch versions
within subjects of the pooled cohorts, which may introduce
more diverse VOC patterns (more noise). However, discrimi-
nation was possible despite these variations. These factors may
also explain, in part, why the BreathCloud cohort was
characterized by higher performance of the models than the
pooled cohorts in both the training and validation sets (with
AUROCCs of at least 0.93 and 0.91, respectively). Another
important factor that may explain the higher performance within
BreathCloud is the real-time capability of capturing the VOCs
compared with that of the offline approach of using the eNose
platform within the pooled cohorts. The latter might be subject
to some contaminant VOCs and/or VOC loss during trans-
portation from the Tedlar bags (SKC, Eighty Four, Pa) and
Tenax tubes (Tenax GR SS 6 mm 3 7 in; Gerstel, M€ulheim an
der Ruhr, Germany).40 Furthermore, the larger sample size in
the BreathCloud study (twice as big as the pooled cohorts)
meant more statistical power and, therefore, better training of
the machine learning models.
The GBM model outperformed both sPLS-DA and adaptive
LASSO in the training sets, which might indicate an overfitting
FIG 4. (Upper panel) AUROCCs with bootstrapped 95% CIs for 3 different machine learning models on
eNose VOC breath profiles from the training subset (;75%) of the pooled cohorts with their associated ac-
curacies, specificities, and sensitivities (95% CIs) are shown. (Lower panel) The predictive potential of the
trained model was evaluated by using a validation subset (;25%) from the pooled cohorts showing rela-
tively high AUROCCs with depiction of their associated accuracies, specificities, and sensitivities
(95% CIs). ALASSO, Adaptive LASSO.
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was observed in the validation sets, suggesting comparable
statistical performance across different machine learning models.
This may indicate robustness of eNose-technology in classifying
patients with atopic asthma despite the use of different machine
learning models.
Studies investigating the relationship between exhaled VOCs
and atopic asthma are scarce. In a previous study, VOC profile
captured by Cyranose C320 showed only a trend (P 5 .07) for
classification between participants with atopic versus nonatopic
childhood asthma.41 This study included only a small sample
size of children with asthma (n 5 31), which may have led to
lack of statistical power. In addition, in our study the Owlstone
Lonestar system is a major driver of the signal that is responsiblefor discrimination, in contrast to the Cyranose C320 (Sensigent,
Baldwin Park, Calif), which was also included in our study.
The atopy-discriminating VOC signals in this study were
probably driven by aeroallergens, as most of the atopic
patients included were sensitized by at least 1 aeroallergen.
This was supported by a sensitivity analysis in which non–
aeroallergen-sensitized patients were excluded, showing
similar findings. Yet, this warrants further investigation to
explore whether the VOC signals detected are related to the
underlying pathophysiology locally (in the lung) or systemi-
cally or both.
FENO values greater than 20 ppb have been reported to be
associated with atopy in 1199 children from Peru who were
aged 13 to 15 years, showing an AUROCC of 0.65 in those
without asthma (n 5 1110) and an AUROCC of 0.82 in those
FIG 5. (Upper panel) The AUROCCs with bootstrapped 95% CIs for 3 different machine learning models on
SpiroNose VOC breath profiles from the training subset (;75%) of the BreathCloud cohort with their asso-
ciated accuracies, specificities, and sensitivities (95% CI) are shown. (Lower panel) The predictive potential
of the trained model was evaluated by using a validation subset (;25%) from the BreathCloud cohort
showing relatively high AUROCCs with depiction of their associated accuracies, specificities, and sensitiv-
ities (95% CI). ALASSO, Adaptive LASSO.
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ABDEL-AZIZ ET AL 1053with asthma (n5 89).38 Our analysis showed that the eNose tech-
nology provided higher AUROCCs in the included pediatric
cohorts (>_0.85 in the U-BIOPRED pediatric cohort and >_0.97 in
the PACMAN2 cohort) and thus provides better accuracy in de-
tecting atopy. In addition, in our study FENO value did not
accurately discriminate between individuals with atopic and non-
atopic asthma (AUROCC 5 0.52), indicating a limited accuracy
of FENO value in detecting atopy as compared with the accuracy
provided by eNose technology in a broad age-range multinational
cohort.
The BN revealed the unsupervised data-driven relationship
between the SpiroNose data points and all other measured
characteristics. From the DAG network, we identified no clear
relationship between exhaled breath profiles associated with
atopy and other measured variables, suggesting that the profilespredicting atopy are not be confounded by other measured factors
in the BreathCloud cohort. In addition, the BN also showed
relationships between VOC signals (from different sensors) and
eosinophil counts and OCS use, as previously reported find-
ings.12,13,42 However, BNs do not prove causality between vari-
ables, and they can be used only for probabilistic reasoning.
Therefore, the association between atopy and exhaled breath
sensor signals is a probabilistic estimation, and further research
to investigate possible confounders is still required.
This study has multiple strengths. First, we used 4 independent
asthma cohorts to validate the findings, which showed a relative
steadiness of the atopy classification potential. Second, the
utilization of different eNose platforms covering both offline
and real-time measurement of exhaled breath may serve as a sign
of generalizability of the eNose technology in detecting atopy in
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that was followed in this study coupled both supervised and
unsupervised approaches to further support findings. Finally, we
used 3 different powerful machine learning techniques to provide
an indication of the robustness of statistical performance across
the models tested.
However, this study also has limitations. First, eNose technol-
ogy in general does not allow for identification of individual
VOCs but is based on cross-reactive sensor arrays that allow
for powerful VOC signal pattern recognition, which does not
hamper the clinical application of eNose technology. Identifying
individual discriminating VOCs in future studies (eg, by mass
spectrometry techniques) will help in getting more insight on the
underlying pathophysiologic pathways. Second, we investigated
only exhaled breath profiles and their relation to atopy at a single
time point. In 1 study, diurnal variations in the VOC profiles of
individuals with moderate atopic asthma were observed.43 There-
fore, assessment of the temporal stability of atopy-discriminative
signature is required. Third, a large percentage of the included
subjects were white, which demands broader investigation in
other ethnicities to assess generalizability. Fourth, validation
should ideally be performed by training a model on a cohort
and then validating the findings on a different cohort. This was
not feasible in the current study, as we used 2 different eNose
technologies (offline versus real-time measurement), which
made direct validation of the findings impossible because of the
different sets of sensors from the 2 technologies. In addition,
because of the limited sample sizes in the data sets of the offline
eNose platform, pooling of the data was essential to achieve the
statistical power necessary for appropriate training and validation
of the models. Fifth, this study was not meant to provide a
comprehensive comparison of the performance of different
machine learning models, but rather to provide an estimate of sta-
tistical robustness as a proof of concept. Whether other models
will provide different outcomes merits further investigation.
Finally, we did not investigate differences in the allergen-
specific VOC signals and whether such signals would differ ac-
cording to the numbers of sensitized allergens, time course of
atopy, and/or levels of specific IgE or wheal size. A previous study
has shown that these atopy-associated outcome measures could
identify subphenotypes within children.44
SPTor allergen-specific IgE measurements remain the criterion
standard for diagnosing atopy and offer details regarding the
allergen to which the patient is sensitized. At this time point, the
eNose cannot be considered an alternative; however, it may offer a
very quick (withinminutes) noninvasive screening tool in situations
in which the standardmethods cannot be used, such as in situations
involving patients with dermatologic conditions, patients taking
interfering medications, and/or patients whose acceptance of skin
testing or blood withdrawal is low (eg, children).
By detecting atopy, in addition to its potential to perceive
changes in inflammatory biomarkers such as eosinophils and
neutrophils or OCS use,12,13 the eNose may help to identify
asthma phenotypes and asthma-associated treatable traits.45
Therefore, it can serve as a tool in precision medicine ap-
proaches to asthma management. Managing atopic asthma
may require different steps ranging from environmental avoid-
ance of allergens46 to symptomatic control with add-on thera-
pies such as antihistamines or antihistamine–leukotriene
antagonist combinations.47 In addition, more targeted therapies,
such as allergen-specific subcutaneous immunotherapy inpatients with stable asthma,48 sublingual immunotherapy, and
the anti-IgE mAb omalizumab,49 can be directed to those pa-
tients with atopic asthma. The use of eNose technology may
thus facilitate noninvasive and quick tailoring of these interven-
tions to the needs of each individual patient.
In conclusion, e-Nose technology can accurately and robustly
classify patients with asthma by atopic status. Coupling super-
vised and unsupervised machine learning approaches revealed
that the associations between exhaled breath and atopy and our
results are generalizable. The findings presented here suggest that
exhaled breath analysis by eNose allows meaningful phenotyping
of patients with asthma andmay therefore be used in personalized
clinical decisions related to asthma.
We would like to acknowledge the help of biostatistician Aruna Bansal,
PhD.
Key messages
d The assertion that signals of exhaled volatile organic com-
pounds, mixtures measured by electronic noses (eNoses),
can adequately classify patients with asthma by atopy is
supported by data from 4 independent asthma cohorts.
d The eNose may serve as a quick, noninvasive tool for
asthma phenotyping.
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